AU2022333099A1 - Gdf15 fusion proteins and uses thereof - Google Patents

Gdf15 fusion proteins and uses thereof Download PDF

Info

Publication number
AU2022333099A1
AU2022333099A1 AU2022333099A AU2022333099A AU2022333099A1 AU 2022333099 A1 AU2022333099 A1 AU 2022333099A1 AU 2022333099 A AU2022333099 A AU 2022333099A AU 2022333099 A AU2022333099 A AU 2022333099A AU 2022333099 A1 AU2022333099 A1 AU 2022333099A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
fusion protein
gdf15
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022333099A
Other languages
English (en)
Inventor
Rongbo CAO
Xiaofeng Chen
Qingwei GONG
Danxia HUANG
Limei Huang
Jing Li
Wenjia LI
Zhaofeng Li
Xiling WEI
Lin Xiao
Jiangyu YAN
Xingguo Yan
Junnan ZENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AU2022333099A1 publication Critical patent/AU2022333099A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022333099A 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof Pending AU2022333099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110977378 2021-08-24
CN202110977378.7 2021-08-24
PCT/CN2022/114096 WO2023025120A1 (en) 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU2022333099A1 true AU2022333099A1 (en) 2024-02-08

Family

ID=85321545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022333099A Pending AU2022333099A1 (en) 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof

Country Status (8)

Country Link
US (3) US20240391971A1 (https=)
EP (3) EP4393940A4 (https=)
JP (1) JP2024532882A (https=)
KR (1) KR20240049337A (https=)
CN (3) CN115925983A (https=)
AU (1) AU2022333099A1 (https=)
CA (1) CA3226178A1 (https=)
WO (3) WO2023025120A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CA2919076C (en) * 2013-07-31 2024-01-30 Amgen Inc. Stabilization of fc-containing polypeptides
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CR20200510A (es) * 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
PE20221316A1 (es) * 2019-10-15 2022-09-07 Dragonfly Therapeutics Inc Proteinas que se unen a nkg2d, cd16 y flt3
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
JP2025504612A (ja) * 2021-12-31 2025-02-13 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｇｌｐ－１及びｇｄｆ１５の融合タンパク質並びにその使用

Also Published As

Publication number Publication date
EP4393941A1 (en) 2024-07-03
EP4393941A4 (en) 2025-10-15
EP4392461A1 (en) 2024-07-03
KR20240049337A (ko) 2024-04-16
CN115925983A (zh) 2023-04-07
JP2024532882A (ja) 2024-09-10
CN115925984A (zh) 2023-04-07
WO2023025123A1 (zh) 2023-03-02
EP4392461A4 (en) 2025-10-15
WO2023025129A1 (zh) 2023-03-02
EP4393940A4 (en) 2025-10-15
EP4393940A1 (en) 2024-07-03
US20240343770A1 (en) 2024-10-17
US20240350588A1 (en) 2024-10-24
CA3226178A1 (en) 2023-03-02
WO2023025120A1 (en) 2023-03-02
US20240391971A1 (en) 2024-11-28
CN115925982A (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
US20250084144A1 (en) Dual-target fusion proteins comprising fgf21 and glp-1, connected through a fc portion of an immunoglobulin
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
EP2697257B1 (en) Fc fusion proteins comprising novel linkers or arrangements
CN1341121A (zh) 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运
WO2018032787A1 (zh) 高糖基化人生长激素融合蛋白及其制备方法与用途
CN110128525A (zh) Fgf21变体、融合蛋白及其应用
WO2023280133A1 (zh) 融合蛋白及其应用
TWI889865B (zh) 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途
US20250179142A1 (en) Fusion protein of glp-1 and gdf15 and use thereof
WO2023025120A1 (en) Gdf15 fusion proteins and uses thereof
CN116948037A (zh) 一种新结构长效卵泡刺激素重组蛋白及其制备和应用
CN114621353A (zh) 一种重组融合蛋白及其应用
US20090270325A1 (en) Growth factor
CN116948036A (zh) 重组孕马血清促性腺激素及其制备方法和应用
HK1045160A (en) Expression and export of anti-obesity proteins as fc fusion proteins
HK40015284A (en) Dual-target fusion proteins comprising the fc portion of an immunoglobulin
HK40015284B (en) Dual-target fusion proteins comprising the fc portion of an immunoglobulin